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INTRODUCTION
Breast cancer has a major impact on the health of women. It is the most 
frequently diagnosed cancer and the second most common cause of cancer death 
in Indian women after cancer of the uterine cervix (Chopra R., 2001). Recently it 
is emerging as the commonest female malignancy in developing Asian countries 
ahead of carcinoma of uterine cervix. Presently 75,000 new cases occur in Indian 
women every year (Chopra R., 2001. loc.cit.).
 The breast cancer has received a great deal of  publicity and has been the 
focus of intensive study. Recently, there has been a slight decline in breast cancer 
mortality due to the early detection of breast cancer in stage I and stage II by 
mammography and effective cancer screening programme. This downward trend 
will continue, if better treatment modalities are followed.
Cytotoxic   chemotherapy  is  a  double-edged  tool.  It  can  increase  life 
expectancy in advanced malignant disease as an adjunct to other therapy but also 
is a hazardous and potentially lethal form of treatment. Assessment of multiple 
prognostic factors is necessary to separate cases which benefit most from this form 
of therapy.
The  clinical  course  of  breast  cancer  varies  considerably  from patient  to 
patient. The median survival of women with untreated breast cancer is 2 to 7 years 
and 10-year survival,  subsequent to the onset of symptoms is 3.6% (Francis E 
Sharkey, et al.,1996).
The pathologist has got critically important responsibilities as a consultant in 
the management of patient with breast cancer. The clinical evaluation estimates 
whether the cancer is localised to breast or whether there are regional or distant 
metastases.  The pathologist,  establishes the diagnosis of cancer and reports the 
significant characteristics which can be used in planning therapy by predicting the 
natural  history  of  the  disease  and  possible  response  to  a  particular  mode  of 
treatment. Another major reason for reporting pathological prognostic features is 
to monitor mammographic screening programmes.
So,  this  study  is  aimed  at  evaluating  certain  architectural,  invasive  and 
proliferative parameters in cases of infiltrating ductal carcinoma of breast.
AIMS AND OBJECTIVES
The aim of this study is to 
1. Stage the cases of carcinoma breast based on the American joint committee 
on Cancer [AJCC] staging system
2. Assess the histological grade of the tumor on the basis of Modified Bloom – 
Richardson grading system
3. Identify the invasive, architectural and proliferative parameters in infiltrating 
ductal carcinoma – breast
4. Correlate clinical staging with the other, pathological prognostic factors.
REVIEW OF LITERATURE
Anatomy :
Breast is a modified sweat gland. It lies in the superficial fascia of the 
pectoral region. It extends from 2nd to 6th rib and from sternal edge to near the mid 
axillary line. A small extension called the axillary tail of Spence pierces the deep 
fascia and lies in the axilla.  Approximately three quarters of the breast is on the 
pectoralis major muscle normally.
Histology :
The functional unit of the breast is called a lobule. There are numerous 
lobules within each breast. A lobule consist of a variable number of acini (glands) 
lined by a double-layered epithelium. 
- Outer flattened myoepithelial cell
- Inner cuboidal cell.
The acini drain into a terminal duct. Each terminal duct and its acini are 
together referred to as the Terminal Duct Lobular 
Unit (TDLU). The terminal duct drains into subsegmental duct, segmental duct, 
and finally into lactiferous duct. There are 15 – 20 Lactiferous duct which open 
into the nipple. Immediately below the nipple, the lactiferous duct dilate to form 
the Lactiferous sinus. The collecting ducts are lined by 2 distinct type of cells – 
basal myoepithelial cell and luminal columnar cell.
Breast carcinoma can occur at any age, but is rare in patients younger than 
25 years. The peak incidence is 45 – 60 years. It is conventional to subdivide 
carcinoma of the breast into two main pathologic categories – in situ carcinoma 
and invasive carcinoma.
American Joint Committee on cancer, divided breast carcinoma into clinical stages 
as follows.
Stage 0 : Carcinoma in situ
Stage I : Invasive carcinoma < 2 cm in diameters without nodal 
involvement.
Stage II : Invasive carcinoma < 5 cm in diameter with upto three 
involved axillary nodes (or) 
Invasive  carcinoma  greater  than  5  cm  without  nodal 
involvement.
Stage III : Invasive carcinoma < 5 cm in diameter with four or  more 
involved axillary nodes (or)
   Invasive carcinoma greater than 5 cm in diameter 
with  nodal involvement;
Invasive carcinoma with 10 or more involved axillary nodes;
  Invasive carcinoma with involvement of ipsilateral 
internal mammary lymph nodes;
  Invasive carcinoma with skin involvement, Chest 
wall fixation or clinical inflammatory carcinoma
Stage IV : Breast cancer with distant metastasis.
For a number of tumors, the role of histopathology in the provision of 
prognostic information has been well established for many years. The main reason 
for this attempted sub classification has been the availability of a range of 
therapies and the need to stratify patients appropriately. In the last decade, the 
treatment of breast cancer has undergone dramatic changes and a much wider 
range of therapeutic options are now available. Early diagnosis, since the advent of 
breast screening, is detecting tumors which are likely to have a favourable out 
come and it has become increasingly important to assess prognosis for each patient 
before a therapeutic plan is agreed.
The following pathologic factors, have been shown to provide clinically 
useful prognostic information to a greater or lesser degree.
1) TUMOR SIZE:
 The diameter of the primary tumor shows a good correlation with the 
incidence of nodal metastases and with survival rate. This easily, quickly and 
cheaply determined parameter has been found to be one of the strongest predictor 
of dissemination and rate of relapse in node negative breast carcinoma. Women 
with node negative carcinomas under 1 cm in diameter have a prognosis 
approaching that of women without breast cancer (Rosai and Ackerman’s Surgical 
Pathology., 2004). The 10-year survival of such women without treatment is 
approximately 90%. On the other hand, over half of women with cancers over 2 
cm in diameter present with lymph node metastases and many of these women will 
eventually succumb to breast cancers (Susan C Lester,et al., 2004).
For correlation with prognosis, the size of tumors should only be assessed on 
pathological specimens, as clinical measurement may be inaccurate. Measurement 
of tumor diameter in three planes should be made to the nearest millimeters, 
initially in the fresh state. After fixation , when the edges of tumor have become 
more clearly defined, the measurements are rechecked and the greatest diameter is 
taken as the tumor size. For small tumors and in cases where there is doubt about 
the definition of tumor margin, the measurement should be further assessed on the 
histological sections using the vernier scale on the microscope stage micrometer.
Patients with small tumor have a better survival than those with large tumors 
(Ellis IO, et al. 1996). Significant correlation was found by Elston CW, et al., 
(1982), Fisher ER, et al., (1984) Neville AM, et al., (1992).
In the long term study from the Memorial Sloan–Kettering Cancer Centre 
the projected relapse-free survival rates for 20 years after initial treatment were as 
follows (Rosen PP, et al., 1990) :
Tumors size 20 yrs relapse free survival rate
< 10 mm 88%
11 – 13 mm 73%
14 – 16 mm 65%
17 – 22 mm 59%
Analysis of size categories in the Nottingham Tenovus study indicates that 
for long term survival the better cut off point is actually at 1.5 cm (Elston CW, et 
al., 1998). In the study by Palmer MK, et al., (1982), patient with a breast tumor 2 
cm or less in maximum diameter had a significantly better survival than patients 
with larger tumor. Rosen PP, et al., (1981) suggested that tumor larger than 1 cm is 
associated with a significantly poorer prognosis. Study by Gohari MR, et al., 
(2006) shows that patients with tumor size larger than 5 cm were in higher risk of 
metastasis compared with others.
2) Excision Margins :
Microscopic examination of the excision margins is usually undertaken to 
assess the adequacy of surgical excision and hence the probability of recurrence. 
The excision margins are usually marked with India Ink, which may track along 
the interstices of the specimen through defects in the surface. It has been found in 
most studies that when tumor reaches the excision margins, there is a significantly 
increased risk of local and distant recurrence (John P. Sloane., 2001).
Schnitt SJ, et al., (1994) in their study defined three categories of adequacy 
of excision (i) positive, in which tumor was present at the inked margins; (ii) close 
- in which the tumor was within 1mm; and (iii) negative - in which the tumor was 
more than 1 mm clear. The 5 year recurrence rate for those with negative, close, 
focally positive and more than focally positive margins was 0%, 4%, 6% and 21% 
respectively. Patients with positive margins have involved lymph nodes at 
presentation and have distant metastasis at 5 years, suggesting that margin 
involvement may be a manifestation of more aggressive disease.
Fourquet A, et al., (1989), found the gross margin involvement to be a major 
risk factor for local recurrence after local excision in multivariate analysis even 
when adjuvant radiotherapy is given.
Wazer DE, et al., (1997) in their study, concluded that the relative closeness 
of tumor to the specimen edge and the extent of margin positivity are predictive of 
residual tumor, though with an error consistent with its limitations as a sampling 
procedure. The histopathology of tumor in the initial excision is predictive of the 
type of residual tumor and the extent of margin positivity was correlated with the 
amount of residual tumor.
The extent of positivity of the excision margin was graded by Wazer DE, et 
al., (1999), according to a four – point scale : focal, minimal, moderate, extensive. 
They suggested that an extent of positivity grade of moderate / extensive is a 
predictor for local recurrence after breast conservation therapy.
Curcio LD, et al., (1999) study suggested that negative surgical margin in 
inflammatory breast cancer and nonmetastatic disease, is associated with a better 
overall outcome. 
3) Histological Types :
Mammary epithelium gives rise to an assortment of carcinoma that number 
between 20 and 30. Classification of these tumors have significant role in 
prognostication. (Gallagen HS., 1994) In 1968, first edition of "Histological typing 
of breast tumors" by WHO was formulated (Scarff RW, et al).
The most common histologic types of Invasive breast carcinoma are ( Dixon 
JM, et al., 1985).
   Histologic types     Distribution
No special type Carcinoma ("ductal") - 79%
Lobular Carcinoma - 10%
Tubular / Cribriform carcinoma - 6%
Mucinous (Colloid) Carcinoma - 2%
Medullary Carcinoma - 2%
Papillary Carcinoma - 1%
Metaplastic carcinoma - < 1%
Other rare types of carcinoma,
- Apocrine carcinoma,
- Carcinoma with neuroendocrine differentiation
- Clear cell carcinomas
- Others
Specific features characterise some breast cancer, while the remaining which 
lack these special features are termed invasive ductal carcinoma of No Special 
Type (NST). It includes the majority of carcinomas (70% to 80%) that cannot be 
classified as any other subtype (Susan C Lester, et al., 2004. loc.cit). The survival 
data for ductal carcinoma (NST), at 10 years ranges from 33 to 48% (Ellis IO, et 
al., 1992).
Infiltrating lobular carcinoma comprises about 10% of invasive breast 
carcinoma (Thomos  J Anderson, et al., 1992). The cells are small and regular. 
There is characteristically single cell infiltration, often in a single file. It has a 
better prognosis than ductal NST carcinoma (Wheeler J.E., et al., 1976). In a study 
of 1621 patients with invasive breast carcinoma, Ellis IO, et al (1992 loc.cit) found 
that the 10-year survival for those with lobular Carcinoma was 54%.
Tubular carcinoma is a low grade breast carcinoma and has well formed 
infiltrating glands with a single cell lining and little cytological atypia with 
abundant stroma. Patients with pure tubular carcinoma have an excellent 
prognosis. Cooper HS, et al., (1985)  recorded a 15 year survival of 100%. In the 
study of Ellis IO, et al., (1992 loc.cit)   the 10-year survival was 90%. 
Cribriform carcinoma has evenly distributed intraepithelial spaces which are 
regular in shape. Venable JG, et al., (1990) found that the 5-year survival with 
infiltrating cribriform carcinoma was 100%. The long term survival with invasive 
cribriform carcinoma appears to be atleast 90% (Ellis IO, et al., 1992. loc.cit).
Mucinous carcinoma has cells floating in mucin pool. Pure mucinous 
carcinoma carry a very good prognosis and the 10-year survival data varies 
between 68% and 90% (Ellis IO, et al., 1992. loc.cit; Clayton F, et al., 1996).
Medullary carcinoma is characterised by a solid syncytium like sheets of 
large pleomorphic tumor cells with a rich lymphoplasmacytic infiltrate and a 
pushing border. Medullary carcinoma of the breast carries a good prognosis. 
Ridolfi RL, et al., (1977) found an overall 84% 10-year survival for medullary 
carcinoma. Similar results have also been recovered by Wargotz ES and Silverberg 
SG (1988). In contrast with these results, a number of other studies have failed to 
demonstrate a significant survival advantage for medullary carcinoma (Fisher ER, 
et al., 1990). Ellis IO, et al., (1992) loc. cit therefore concluded medullary 
carcinoma should be regarded as having a moderate prognosis.
Invasive papillary carcinoma with papillary architecture is a very rare tumor. 
Fisher ER, et al., (1980) and Mc Divitt RW, et al., (1968) concluded that it carries 
a favourable prognosis.
Metaplastic carcinoma – a group of tumors in which the malignant epithelial 
cells show evidence of metaplasia to mesenchymal cells or epithelial cells not 
normally found in the breast, is a rare tumor. It behaves as highly malignant 
tumors with early recurrence and poor survival (Ellis IO, et al., 1996. loc.cit).
In summary, patient with the common histological types of breast carcinoma 
may be stratified into four broad prognostic groups (Ellis I, 1997).
Rating Prognosis 10 – yr survival Type of Carcinoma
Excellent > 80% Tubular, Cribriform, 
Mucinous 
Good 60 to 80% Mixed ductal NST 
with special type
Moderate 50 – 60% Medullary, Invasive 
Papillary, Lobular
Poor < 50% Ductal NST
4) Vascular Invasion
Tumors stimulate the growth of host blood vessels, a process called 
angiogenesis, which is essential for supplying nutrients to the tumor. Vascular 
invasion is more common in this situation and large veins may be involved by 
intravascular growth of tumor. Penetration of small lymphatic and blood vessels is 
associated with a poor prognosis and involvement of large veins with intravascular 
extension of tumor have the potential of releasing tumor cell aggregates or emboli 
into the venous circulation. These large tumor cell aggregates have been 
demonstrated to be associated with a higher efficiency of metastasis formation and 
infer a poorer prognosis. Many malignant cells are being released into the 
circulation of cancer patients and few, if any ever successfully complete the 
complex sequence leading to a metastatic focus.  This has been termed “metastatic 
inefficiency”. The finding of occasional small aggregates of single tumor cells in 
vascular spaces statistically implies that a considerable number of cells must be 
entering the vascular compartment (Crissman JD., 1986).
Conflicting view have been expressed concerning the prognostic value of 
estimating  vascular  invasion  in  breast  cancer.  Some  studies  have  found  no 
correlation (Dawson P, et al., 1982) while others have shown that the presence of 
vascular invasion predicts both recurrence and long-term survival. It may be due to 
the wide variation in the reported frequency of vascular invasion and the related 
problem of the distinction of true vessels from artifactual soft tissue spaces (Ellis 
IO, et al., 1996. loc.cit.).
Tumor emboli are mainly seen within thin walled channels. Since it is almost 
impossible to determine whether such spaces are lymphatics or venules the broad 
term “vascular  invasion” is  used (Elston CW, et  al.,  1998.  loc.cit).  The major 
problems  lie  in  over  looking  small  tumor  emboli  in  capillary  vessels  and 
distinguishing  them  from  masses  of  tumor  exhibiting  retraction  from  the 
surrounding stroma as a result of processing artifact (John P. Sloane. 2001). These 
problems can be greatly reduced by obtaining good fixation and by working to 
simple but strict criteria. The determination of vascular invasion should only be 
made in tissue adjacent to the tumor mass and not within it. Tumor emboli must be 
seen within  spaces  having a  clear  lining of  endothelial  cells;  these  spaces  are 
usually  located  within  connective  tissue  separated  from  mammary  lobular 
elements by interlobular stroma and are often in close proximity to small muscular 
blood vessels (Elston CW, et al., 1998. loc.cit).
Examination of hematoxylin and eosin stained sections is the most reliable 
method for identifying vascular invasion in breast cancer (Pinder S, et al., 1994). 
Reticulin stain can be used. Immunostaining for endothelial markers [CD 31 and 
CD 34] should be reserved for equivocal cases (Bettelheim R, et al., 1984b).
Most researchers have found a significant relationship between the presence 
of  vascular  invasion and prognosis  as  judged by local  recurrence,  disease-free 
survival or overall  survival (Pinder S, et  al.,  1994. loc.cit;  Davis B.W. 1985) . 
Vascular  invasion has also been shown to be  a predictor  of  lymphnode status, 
tumor grade and size, but not of estrogen receptor status (Pinder S, et al., 1994. 
loc.cit; Orbo A, et al., 1990). Vascular invasion also shows a high correlation with 
tumor type, development of distant metastasis and poor prognosis (Lee AKC, et 
al.,  1986).  Weigand  RA,  et  al.,  (1982),  examined  blood  vessel  invasion  and 
axillary lymph node involvement in 175 breast cancer patients and concluded that 
blood vessel  invasion is a  useful  indicator of early recurrence in patients with 
primary  breast  cancer  and  in  combinations  with  node  status  is  a  prognostic 
indicator with high discriminatory power.
Van  den Eynden  GG,  et  al.,  (2006)  used  anti-CD34 as  pan endothelium 
marker and demonstrated that it is possible to distinguish between blood vessel 
invasion and lymph vessel invasion in breast  cancer specimens. In multivariate 
analysis, peritumoral lymph vessel invasion was the only independent determinant 
of lymph node metastasis.
5) Lymph Node Stage :
Axillary  lymph  node  status  is  the  most  important  prognostic  factor  for 
invasive carcinoma in the absence of distant metastasis. The clinical assessment of 
nodal  involvement  is  very  inaccurate  with  both  false  positive  findings  [eg. 
palpable reactive nodes]  and false negative findings [eg., lymph nodes with small 
metastatic deposits]. Therefore, biopsy is required for accurate assessment (Susan 
C Lester, et al., 2004. loc.cit).
Numerous  studies  have  shown  that  patients  who  have  histologically 
confirmed loco-regional lymph node involvement have a poorer prognosis than 
those without nodal involvement. On average, 10-year survival is reduced from 
75% for patients with no lymph node involvement to 25 – 30% for those with 
lymph node metastasis (Carter GL, et al., 1989; Veronesi U, et al., 1993).
Prognosis is also related to the overall number of loco-regional lymph nodes 
involved (Elston CW, et al., 1998). Fisher ER, et al., (1978), in their study have 
also concluded that survival is more likely related to the number of nodes involved 
rather than the size of the deposit. For prognostic purpose the best grouping seems 
to be the following (Rosai and Ackerman’s Surgical Pathology., 2004 loc. cit.).
1 – Negative nodes.
2 – One to three positive nodes
3 – Four or more positive nodes
With no nodal involvement the 10-year disease-free survival rate is close to 
70% to 80%; the rate falls to 35% to 40% with one to three positive nodes and 
10% to 15% in the presence of more than 10 positive nodes (Susan C Lester, et al.,  
2004. loc.cit).
The level of nodal involvement also provides useful prognostic information; 
metastasis to the higher level in the axilla and specifically the apex, carriers a 
worse prognosis. Careful manual dissection of fixed axillary adipose tissue is the 
most cost effective method for isolating lymph nodes for microscopic examination 
(Rosen PP. 1991).
In the study by Jatoi I, et al., (1999) they concluded that nodal metastasis is 
not only a marker of diagnosis at a latter point in the history of breast cancer, but 
also a marker of aggressive phenotype.
6. Histological grade :
Greenhough RB(1925.loc.cit) was the first to evaluate histological grading 
in breast cancer by assessing eight different morphological factors – the amount of 
gland formation, the presence of secretory vacuoles,  cell size, nuclear size, 
variation in the size of both cells and nuclei, the degree of hyperchromatism and 
the number of mitosis. Scarff RW, et al., (1928.loc.cit) emphasised on the amount 
of tubule formation, inequality in the size of nuclei, hyperchromatism. The mitotic 
figures was considered to be of less importance.
In 1957, Bloom HJG, a radiotherapist and Richardson, a surgical research 
fellow introduced a numerical scoring system in histological grading; Each of the 
three factors – tubule formation, nuclear morphology and mitosis, was scored on a 
scale of 1 to 3, giving a possible total score of 3 to 9 points. Grade was allocated 
by an arbitrary division of the total points. 
This  Patey  and  Scarff  method,  modified  by  Bloom and  Richardson  was 
adopted  as  the  preferred  grading  system by  the  WHO (Ellis  IO,  et  al.,  1992 
loc.cit). The statistical analysis shows that the WHO – grading proves to be the 
most indicative prognostic factor next to the number of affected lymph nodes and 
tumor size (Schnurch HG, et al., 1985).
Black MM, et al., (1955) re-evaluated the method which Bloom HJG (1950) 
advocated and concluded that nuclear morphology was most important. Since both 
architecture (Bloom – Richardson system) and cytology [Black] have been found 
to correlate with prognosis, the sensible proposal has been made to use them in 
conjunction  (Lash  RH,  et  al.,  1986).  Elston  has  been  the  champion  of  this 
approach,  which  is  usually  referred  to  as  the  Nottingham modification  of  the 
Bloom – Richardson system and which also incorporates the evaluation of mitotic 
activity (Elston CW, et al., 1990; Frierson HF, et al., 1995).
The grading criteria for this system are:
i). Tubule formation :-
Only  structures  with  a  clearly  defined  lumen,  indicative  of  ductal  or 
glandular differentiation are included. Spaces formed as a consequence of other 
mechanism,  such  as  poor  cell  cohesion or  cellular  necrosis  are  excluded.  The 
following  percentages  refer  to  the  area  of  the  carcinoma  exhibiting  tubule 
formation for each of the three scores :
1 = more than 75%
2 = between 10% and 75%
3 = Less than 10%
ii) Nuclear pleomorphism :
In order to introduce a degree of objectivity, the size and shape of normal 
epithelial cells present in breast tissues adjacent to the tumor should be used as a 
reference point. If normal epithelial structures are not present in the tumor section, 
then it  is  usually  possible  to  find  inflammatory  cells  such as  lymphocytes for 
comparative purpose. Allowance should be made for the fact that lymphoid cells 
have a relatively smaller overall size than epithelial cells. The following criteria 
are used :
• 1 = The nuclei are small and exhibit little increase in size over that of normal 
breast  epithelial  cells.  They  have  regular  outlines  and  uniform  nuclear 
chromatin and show  little variation in size.
• 2 = The cells are significantly larger than normal with open vesicular nuclei, 
discernible nucleoli and moderate variability in size and shape.
• 3 = The nuclei are large and vesicular, often with prominent nucleoli, show a 
marked variation in size and shape and occasionally exhibit very large and 
bizarre  forms.
iii) Mitotic counts :-
Hyperchromatic nuclei  is more likely to indicate  individual cell  necrosis 
(apoptosis) than proliferation, and such nuclei should be excluded from the counts. 
Only figures, which clearly fulfill the morphological criteria  for the various stages 
of mitosis  –  prophase,  metaphase,  anaphase and telophase,  are included in the 
count (Elston CW, et al., 1998. loc.cit).
A minimum of 10 fields is counted at the periphery of the tumor where it has 
been  demonstrated  that  proliferative  activity  is  greatest  (Verhoeven  D,  et  al.,  
1990).
A score of 1 is given for a count of 5 or fewer mitosis per 10 high power 
fields. Score of 2 for a count of 6-10. A score of 3 for more than 10 (Elston CW, et 
al., 1998 loc.cit.).
Allocation of grade :
To obtain  the  overall  tumor  grade  the  scores  for  each  factor  are  added 
together giving a possible total of 3 – 9 points. Tumor grade is then allocated on 
the following basis.
Points Grade
3 – 5  I – well differentiated 
6 – 7 II – moderately differentiated 
 8 – 9 III – poorly differentiated 
7. HORMONE RECEPTORS :
Carcinoma of the breast is often responsive to hormones, a property which 
has  been  exploited  through  endocrine  surgery  and  more  recently  using  drugs 
which influence hormone levels or inhibit the effects of hormones on tumor cells 
(Elston CW, et al., 1998 loc.cit).
Steroid receptors such as estrogen and progesterone receptor are located in 
the cell nucleus. Hormone is believed to diffuse or be transported to the nucleus 
where  a  steroid  receptor  complex  is  formed.  Some of  the  genes  regulated  by 
steroid receptors are involved in controlling cell growth and it is currently believed 
that  these  effects  are  the  most  relevant  to  estrogen  receptor  influences  on the 
behaviour and treatment of breast cancer (Elston CW, et al., 1998. loc.cit.).
Tamoxifen, an anti-estrogenic drug is the most widely used agent and it acts 
by inhibiting the action of hormones in their target tissues. The demonstration that 
radio-labeled estradiol  is  bound to some breast  cancer specimens and that  this 
effect  was  related  to  response  to  hormone ablation  led  to  the  development  of 
hormone receptor assays directed at identification of patients suitable for hormone 
therapy.
Estrogen  Receptor  (ER)  and  Progesterone  Receptor  (PR)  assay  helps  in 
predicting the response to hormone therapy (Cancer, 1980).
ER positive PR positive tumors have a 78% response
ER negative PR positive tumors have a 45% response
ER negative PR negative tumors have a 10% response
Evidence of significant benefit from endocrine treatment has been observed 
in patients whose tumors contain as few as 1% positive cells (Clark GM, et al., 
1997).  Elledge RM and Osborne CL (1997) have argued that when the cut-off 
point is stringently low and the assay is of high quality, patients with ER-negative 
tumors will experience little or no benefit from tamoxifen, especially when it is 
used as adjuvant treatment, significant financial saving can thus be made by not 
using the drug indiscriminately.
The cytosol ligand binding assay has until recently been the standard assay 
method but has a number of disadvantages - large amount of tissue is required and 
is  affected  by  high  endogenous  levels  of  estradiol.  With  the  development  of 
monoclonal antibodies specific for the receptor protein, the immunocytochemical 
method has superseded the ligand binding assay, as they require less tissue, allow 
formal histological assessment (King WJ, et al., 1984; Goulding H, et al., 1995) 
and may be used on very small sample such as fine needle aspirates (Robertson 
JFR, et al., 1992). 
Rich MA, et al., (1978), Hahnel R, et al., (1979) and Aamdal S, et al., (1994) 
in their study suggested that the estrogen receptor content of human breast cancer 
specimen  is  related  to  the  degree  of  differentiation  (grade)  of  the  tumor.  In 
addition,  patients  with  estrogen  receptor  –  positive  tumors  experience  fewer 
recurrences and remain disease free for a longer period of time than do patients 
with  receptor  negative  tumors.  But  this  advantage  gradually  disappeared  with 
increasing interval after mastectomy.
Chang JC, et al., (1981) study suggest that ER+ status has a beneficial effect 
in  the  responsiveness  of  advanced  breast  cancer  to  chemotherapy  of 
Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) and is prognostic of 
better survival. Clark GM, et al., (1983) found that PR was more important than 
ER in predicting disease-free survival for a group of patients with stage – II breast 
disease. Bernoube A, et al., (1998) in their study concluded that the disease-free 
interval and the metastasis-free survival tended to be worse for ER –/ PR – than 
for ER – / PR+ patients during the first 5 years.
8. ARGYROPHILIC NUCLEOLAR ORGANIZER REGIONS 
(AgNORs) :
The degree of malignancy of an individual neoplasm cannot be predicted 
with certainity by simple microscopic analysis alone. The criteria by which degree 
of  malignancy is  assessed [eg.  nuclear  pleomorphism,  nucleocytoplasmic ratio, 
polarity loss and mitotic frequency] are often unsatisfactory in individual tumors. 
Accordingly newer methods have been developed for describing malignancy more 
objectively which include :-
i). DNA flow cytometry – the amount of DNA per nucleus is assessed.
ii) Labeling replicating cells with monoclonal antibodies like Ki – 67;   BK 19.9.
iii) The AgNOR technique.
      Nucleolar organizer Regions (NORs) are specific portions of DNA, called 
rDNA that, by using the enzyme RNA-polymerase-1, code for the transcription of 
ribosomal RNA (rRNA) (Crocker J, 1992). This latter then forms ribosomes and 
these ultimately assemble proteins . The NORs can be seen close to the centromere 
as  a  ‘secondary  constriction’ in  conventionally  prepared  chromosomes  or  by 
hybridization  methods,  but  are  usually  demonstrated  by  the  binding  of  their 
associated protein to silver [Ag++] ions.  The chromosome preparations,  cells  or 
paraffin  tissue  sections  are  exposed  to  a  silver  formate  colloid  stabilized  by 
gelatin, which enables the Ag++   ions to bind to the Nucleolar organizer Regions 
Associated  Proteins  [NORAPs]  –  a  technique  described  by  Good  pasture  and 
Bloom in  1975,  modified  by  Ploton,  et  al.,  in  1986.  This  is  called  ‘AgNOR’ 
reaction and all reaction sites ‘AgNORs’ (Crocker J, 1992.loc.cit.).
This technique is very simple and does not require special preservation or 
fixation of tissue. It can be performed on formalin – fixed, paraffin – embedded 
section (Ajay K Khanna, et al., 2005).
Silver  stained  slides  were  examined  under  light  microscope  at  100x 
magnification  AgNORs  appear  as  brown  or  black  dots  within  a  yellowish 
background of nucleus. The number of dots in 100 cells should be counted and the 
average is often referred to as mAgNOR (mean AgNOR) (Ajay K Khanna, et al., 
2005). The number of AgNOR rises with the increasing proliferative activity of 
cells (Morgan DW, et al., 1998). Thus, compared to normal or benign lesions, the 
number of AgNOR dots in malignant lesions is higher (Uno T, et al., 1988). Due to 
the  simple  quick  and  convenient  nature,  this  method  has  been  used  in 
histopathological diagnosis of  various benign and malignant human tumors ,such 
as breast prostate and salivary gland tumors (Ghomette GP, et al., 1991; Morgan 
DW, et al., 1998 loc.cit).
 Most  AgNOR studies  focus on the  difference in  AgNOR counts  among 
tumors of different pathological grades and tissues in different stages of neoplasia 
i.e. dysplasia ,in situ carcinoma or invasive carcinoma (Mulazim Hussain Bukhari, 
et al., 2007). Roller E, et al., (1993), in their study found  a clear  cut difference 
between benign breast  diseases as compared with breast  carcinomas where the 
mean AgNOR count was significantly higher.
9. Nottingham Prognostic Index :
Until comparatively recently, the only factor used consistently as a guide for 
therapy has been locoregional lymph node status. Lymph node status is a time-
dependent prognostic factor and the longer a tumor has been growing the more 
likely it is that spread to lymph nodes have occurred. Although lymph node status 
is a ‘powerful factor’, it takes no account of the innate aggressiveness of tumors.
The  aggressiveness  of  a  tumor  depends  on  a  number  of  biological 
characteristics  like  differentiation,  growth  rate,  hormone  responsiveness.  If 
accurate  prognostication  is  required  on  an  individual  patient  basis  then  a 
prognostic  index  is  required  which  uses  both  time-dependent  factors  and 
biological factors.
Greenhough RB (1925 loc.cit.), he noted that the combination of high grade 
malignancy and lymph node involvement gave an exceedingly poor  prognosis. 
Bloom HJG (1950 loc.cit.) too stressed that prediction of survival was improved 
by combining grade with stage. The 5-year survival of 94% for patients with grade 
I tumors and uninvolved nodes fell to 65% for those with involved nodes and for 
patents  with  grade  III  tumors  from  55%  to  16%.  Similar  findings  were 
subsequently reported by Elston CW (1982 loc.cit.).
In a study of nine putative prognostic factors in nearly 400 patients with 
primary  operable  breast  cancer,  Haybittle  JL,  et  al.,  (1982)  found  that  several 
showed a significant relationship to prognosis, but only three – size, grade and 
lymph  node  status  –  remained  significant  on  multivariate  analysis.  Using  the 
coefficients of significance for these three factors, an index predicting survival, 
that become known as the Nottingham Prognostic Index [NPI] was calculated :
NPI = 0.2 x size (in cm) + lymph node stage [1-3] + grade [1-3]
The higher the value for NPI the worser the  prognosis. Curves of survival by 
life table analysis showed excellent separation of patient groups, depending on 
the index value. Three groups of patients have been identified by employing 
(arbitrary) cut – off points.
Prognosis NPI
Good < 3.4
Moderate 3.41 – 5.4
Poor > 5.41
A number of subsequent prospective studies have been undertaken to review 
the efficiency of the index in predicting the clinical outcome of an increasingly 
large  number  of  patients  with  increasingly  long follow-up times [Todd,  et  al., 
1987; Grade, et al., 1992]. The graph:1 shows a recent update of the Nottingham 
services.  An excellent  prognostic  group has also been recently  defined to  take 
account of patients whose tumors have been detected by screening.
Galea MH, et al., (1992) gave a simplified therapeutic guide based on the 
index. The efficiency of the index has been confirmed by workers in other centers 
(Baslev I, et al., 1994). The main strength of NPI lies in the fact that it is based on 
relatively simple data which can be provided in routine histopathology laboratory.
Graph1: showing survival according to Nottingham prognostic index.
GPG= good prognostic group
MPG= moderate prognostic group
PPG= poor prognostic group
MATERIALS AND METHODS
This  study  was  carried  out  in  the  Department  of  Pathology,  Tirunelveli 
Medical College, Tirunelveli, during the period of December, 2005 to April, 2007.
A total  number  of  80  cases  of  breast  carcinoma  who  have  undergone 
mastectomy with axillary clearance was included in the study .
The age group varied from 24 years to 76 years with the mean age of 49.4 
years. Preliminary slicing was done within 2 hours of surgery to allow adequate 
penetration of the fixative. The exision margins were marked with India ink. A 
detailed study on the morphological features was done with the specimen and the 
findings were recorded in a proforma. Emphasis was given to the size of tumor. 
The  distance  from the  nearest  excision  margin  was recorded.  As  many lymph 
nodes as possible was dissected from all the specimens.
Adequate  tissues  samples  were  taken  from  the  tumor  periphery,  and 
resection margin closest  to  the  tumor.  Nodes less  than 5mm in diameter  were 
embedded intact, those greater than 5 mm were cut into slices not exceeding 5 
mm. The tissues were embedded in paraffin blocks and 3-5 µm thick sections were 
cut  in  a  rotary  microtome  and  the  slides  were  stained  with  conventional 
Haematoxylin and Eosin stain for the evaluation of histologic factors. Additional 
slides  were  subjected  to  special  staining  techniques  with  silver  to  assess  the 
vascular  invasion and to qualify the Argyrophilic  Nucleolar  Organizer Regions 
(AgNORs)  In  randomly  selected  20  cases  estrogen  receptor  and  progesterone 
receptor  study  was  also  undertaken,  by  immunohistochemical  evaluation  of 
paraffin embedded tissues using monoclonal antibody.
Staging was done based on American Joint Committee on Cancer System. 
The salient features of prognostic importance that were assessed include.
1) Architectural features
i) Tumor size
ii) Resection margin involvement
iii) Histological type
2) Invasive features
i) Vascular Invasion
ii) Lymph node deposits.
3) Proliferative features 
i) Histological grade
ii) AgNOR
iii) Nottingham prognostic index.
The data obtained were recorded and tabulated in a proforma and were 
analyzed statistically.
RESULTS
Table 1 : Age 
Age Group (in years)
Cases
No. %
Less than 20 - -
20-29 3 3.7
30-39 9 11.3
40-49 20 25.0
50-59 31 38.8
60 and Above 17 21.2
Total 80 100
Mean 49.4 years
Table 1 Shows the incidence of breast carcinoma in different age groups in our 
study. The youngest was 24 years and the oldest was 76 years. The mean age was 
49.4 years. Maximum number of cases (38.8%) were seen in the age group of 50 – 
59 years; 85% cases were above 40 yrs.
Table 2 : Stage
Stage CasesNo. %
I
II
III
IV
5
27
44
4
6.3
33.7
55.0
5.0
Table  2 Shows the percentage of cases in each stage in our study. Maximum 
number of 44 cases (55%) were of stage III, followed by stage II with 27 (33.7%) 
cases. 
Table 3 : Histological type
Histological type CasesNo. %
IDC
Lobular
IDC with comedo pattern
Others
          Lymphoma
          Medullary
          Papillary
          Neuro endocrine 
     Mucinous
     Others Total
66
6
3
1
1
1
1
1
5
82.5
7.5
3.7
1.3
1.3
1.3
1.3
1.3
6.3
IDC (NST) = Invasive Ductal Carcinoma (No Special Type)
Table 3 Shows the number of cases in each histological type of breast carcinoma. 
Maximum number of 66 cases (82.5%) were of IDC (NST). 6 cases (7.5%) were 
of lobular type, 3 cases (3.7%) were of IDC with comedo pattern. There was 1 
case (1.3%) each of the other special sub types – Lymphoma, Medullary, Papillary, 
Mucinous and Neuroendocine carcinoma.
Table 4: Histological Grade
Histological Grade             
( grading done for 69 
cases)
Cases
No. %
I
II
III
4
38
27
5.8
55.1
39.1
Table 4 Shows the percentage of cases in each grade of invasive ductal carcinoma. 
Maximum number of 38 (55.1%) cases were of grade II, 27 cases (39.1%) were of 
grade III and 4 cases (5.8%) were of grade I tumor.
Table 5: ER, PR status
ER,PR
Cases
No. %
ER+ PR+
ER+ PR-
ER- PR+
ER- PR-
5
2
7
6
25
10
35
30
ER = Estrogen Receptor ; PR = Progesterone  Receptor
Table 5 Shows the ER, PR status in 20 breast carcinoma cases. 25% of cases were 
positive for both, while 30% of cases were negative for both. 35% of cases were 
positive for PR only and 10% of cases were positive for ER only.
Table 6: Lymph Node Stage
Lymph Node Stage
Cases
No. %
Stage I 
Stage II 
Stage III 
28
33
19
35
41.4
23.6
Table 6 Shows the percentage of cases in each lymph node stage. 35% cases were 
of lymph node stage I, 41.4% of cases of stage II and 23.6% of cases of stage III 
lymph node status.
Table 7: Nottingham Prognostic Index 
NPI CasesNo. %
Good ( < 3.4 )
Moderate ( 3.5 – 5.4 )
Poor ( > 5.4 )
20
24
25
29
34.8
36.2
NPI = Nottingham Prognostic Index
Table 7 Shows the percentage of cases belonging to each group of NPI score. 29% 
of cases were of good prognostic group, 34.8% were of moderate and 36.2% were 
of poor prognostic group.
Table 8 : Age and Stage
Stage Age in yearsMean S.D.
I 56.8 4.4
II 51.3 11.3
III 47.9 9.4
IV 40.8 11.7
‘p’
0.0319
( Significant )
Table 8 Shows the correlation between age of the patient and stage of the tumor. 
Table 9 : Staging and Histological grade
Stage Histological Grade (69 cases)
I II III
No. % No. % No. %
I 3 100 - - - -
II - - 21 100 - -
III 1 2.4 17 40.5 24 57.1
IV - - - - 3 100
Table 9 Shows the correlation between TNM staging and modified Bloom and 
Richardson (Nottingham) grading. All of the stage I cases were of grade I and all 
of stage II disease were of grade II. Among stage III cases, 2.4% were of grade I, 
40.5% were of grade II and 57.1% were of grade III. All the stage IV cases were of 
grade III.
Table 10 : Size and Grading
Grade Size in cmsMean S.D.
I 3.08 2.62
II 5.55 2.13
III 8.2 2.62
‘p’ 0.0001
( Significant )
Table 10 Shows average size of tumor in each grade of breast carcinoma. The 
mean size of tumor in grade I cases was 3.08 cm, grade II cases was 5.55 cm, 
grade III was 8.2 cm. This was found to be statistically significant.
Table 11 : Size and Lymph Node Status
Lymph Node Stage
Size in cms
Mean S.D.
I 
II 
III
5.65
5.5
8.13
3.0
1.96
2.69
‘p’ 0.0018
( Significant )
Table 11 Shows the correlation between size of the tumor and lymph node stage. 
The mean size of the tumor was 5.65 cm in lymph node stage I, 5.5 cm in stage II 
and 8.13 cm in stage III cases. This was found to be statistically significant.
Table 12. Resection Margin with Clinical Stage and Histological Grade
RM Stage Grade
Involved
I II III IV I II
No. - 3 14 3 1 5
% - 11.1 31.8 75 - 13.2
Free No. 5 24 30 1 4 33% 100 88.9 68.2 25 100 86.8
RM – Resection Margin 
Table 12 Shows the percentage of cases in each stage and in each grade with 
resected margin involvement. The resected margin was involved in 75% of stage 
IV case, 31.8% of stage III and 11.1% of stage II cases.  The resected margin was 
involved in 13.2% of grade II and 48.1% of grade III cases.
Table 13 : Histological grade and Vascular Invasion
Histological Grade
Vascular Invasion
Present Absent
No. % No. %
I 2 50 2 50
II 19 50 19 50
III 19 70.4 8 29.6
Table 13 Shows the percentage of each grade of breast carcinoma with vascular 
invasion. Vascular invasion was present in 70.4% of grade III cases.
Table 14 : Vascular Invasion and Lymph Node Stage
Vascular Invasion
Lymph Node Stage 
I II III
No. % No. % No. %
Present
Absent
6
22
21.4
78.6
23
10
69.7
30.3
18
1
94.7
5.3
Total 28 100 33 100 19 100
Table 14 Shows the percentage of different lymph node stage cases with vascular 
invasion. Vascular invasion was present in 21.4% of lymph node stage I, 69.7% of 
stage II and 94.7% of stage III cases.
Table 15 : Histological Grade and Lymph Node Stage
Lymph Node 
Stage
Histological Grade
I II III
No. % No. % No. %
I 
II 
III
2
2
-
50
50
-
17
19
2
44.7
50
5.3
5
6
16
18.5
22.2
59.3
Total 4 100 38 100 27 100
Table 15 Shows the correlation between lymph node stage and histological grade. 
50% of grade I cases were of lymph node stage I and 50% of stage II. 50% of 
grade II cases were of stage II, 44.7% were of stage I and 5.3% were of stage III.  
Among grade III cases, 18.5% were stage I, 22.2% were stage II and 59.3% were 
stage III.
Table 16 : Stage and NPI
Stage
NPI
Mean S.D.
I 1.97 1.24
II 3.57 0.96
III 5.62 1.67
IV 7.85 0.44
‘p’ 0.0001
( Significant )
NPI = Nottingham Prognostic Index
Table 16 Shows the correlation between TNM staging and NPI of Invasive ductal 
carcinoma of Breast. The mean NPI was 7.85 for stage IV case, 5.62 for stage III, 
3.57 for stage II  and 1.97 for stage I  cases.  This was found to be statistically 
significant.
Table 17 : Stage and AgNOR
Stage
AgNOR
Mean S.D.
I 2.52 0.11
II 2.84 0.19
III 3.2 0.26
IV 3.28 0.59
‘p’ 0.0001
( Significant )
AgNOR = Argyrophilic Nucleolar Organizer Regions 
Table  17  Shows  the  correlation  between  TNM staging  and  the  mean  AgNOR 
value. The mean AgNOR value was 2.52 in patients with stage I tumor, 2.84 in 
stage II, 3.2 in stage III and 3.28 in stage IV. This was found to be statistically  
significant.
Table 18 : Histological type and AgNOR
Histological type
AgNOR
Mean S.D.
IDC [NST] 3.07 0.32
Lobular 2.7 0.2
IDC with comedo pattern 3.47 0.21
Others 2.78 0.28
‘p’ 0.0023
( Significant)
AgNOR = Argyrophilic Nucleolar Organizer Regions 
IDC [NST] – Invasive Ductal carcinoma (No Special Type)
Table 18 Shows the correlation between AgNOR and histological types of breast 
carcinoma cases. The mean AgNOR value was 3.47 in IDC with comedo pattern, 
3.07 in IDC [NST], 2.7 in patients with Lobular carcinoma and 2.78 in patients 
with other special types. This was found to be statistically significant.
Table 19 : Histological grade and AgNOR
Histological Grade
AgNOR
Mean S.D.
I 2.53 0.13
II 2.93 0.2
III 3.4 0.16
‘p’ 0.0001
(Significant)
AgNOR = Argyrophilic Nucleolar Organizer Regions 
Table 19 Shows the correlation between the grade and AgNOR value of breast 
carcinoma cases. The mean AgNOR value for grade I cases was 2.53, grade II 
cases  was  2.93  and  for  grade  III  was  3.4.  This  was  found  to  be  statistically 
significant.
Table 20 : AgNOR and NPI
NPI
AgNOR
Mean S.D.
Good 2.85 0.27
Moderate 3.03 0.22
Poor 3.35 0.26
‘p’ 0.0001
(  Significant )
NPI = Nottingham Prognostic Index
AgNOR = Argyrophilic Nucleolar Organizer Regions 
Table  20  Shows  the  correlation  between  AgNOR and  NPI.  The  patients  were 
divided into 3 groups-Good, Moderate and poor prognostic groups based on the 
NPI score. The average AgNOR value in patients belonging to good prognostic 
group was 2.85, Moderate group was 3.03 and poor group was 3.35. This was 
found to be statistically significant.
DISCUSSION
Age : 
The mean age of the patients included in our study was 49.4 years (Table 1). 
This is lesser than the observation made by Rhodes DJ, (2002), who found that 
more than 75% cases presented with the age of 50 and above and the mean age 
was 64 years.
Vinod.R, et al., (2005) had a similar observation of a mean age of 47 years, 
which correlates  well  with  our  study.  These  results  indicate  that  carcinoma of 
breast in Indian subcontinent have a lower mean age compared with the western 
figures.
Age and stage :
In our study, we correlated the age of the patient  to the clinical  stage at 
presentation and we found that the mean age was high in patients with stage I 
disease when compared with the mean age of women with stage IV disease. It was 
also found to be statistically significant (p value = 0.0319) (Table :8).
This observation was similar to that of Foo CS, et al.,  (2005),  who 
found that the younger patients have tumors with higher clinical stage and poorer 
prognostic  profile.  Jakic  –  Rezumovic  J,  et  al.,  (2005)  showed  that  there  is 
statistically significant correlation between patients age and stage of disease with 
patients survival.  
But  younger  women  do  not  have  a  poorer  overall  survival  due  to  the 
aggressive adjuvant therapy to which they are subjected.
Histological Types:
The correct classification of many of the histological types depends on the 
adequacy of tissue sampling.
A carcinoma is generally classified as invasive ductal carcinoma-No  Special 
Type (NST) if  the histological features of the special type constituted less than 
10% and the tumor is termed as mixed if the special feature form between 10% 
and 90%. If the special histological features form more than 90% of the tumor area 
studied then the tumor is claimed as one of the special subtype. The identification 
of special histological subtype is of value due to the differences in tumor 
behaviour pattern of the various special types of breast carcinoma.
In our study, invasive ductal carcinoma (NST) constituted the highest 
number of cases (82.5%) of the total cases studied (Table :3).
This correlates well with the study of Dixon JM, et al., (1985. loc.cit.), who 
had reported an incidence of 79% in a study on the long term survival of breast 
cancer. In another larger series Ellis, et al., (1992. loc.cit.) assigned 47% of the 
tumor to this category.
Invasive lobular carcinoma contributed 7.5% of the total cases studied. This 
correlates with the observation of Dixon JM, et al., (1985. loc.cit.) who observed 
10% of cases in his study.
Necrosis is not a prominent feature in most ductal carcinoma (NST). Rapidly 
growing densely cellular lesions may undergo intensive central necrosis producing 
a comedo pattern of necrosis. 3 cases (3.7%) of our study showed this specific 
histological pattern.
We had a single case of medullary carcinoma (1.3%) of the total cases 
analysed. This goes very well with the observation of Dixon JM, et al., (1985. 
loc.cit.) who found 2% of breast carcinoma had medullary pattern. The reported 
incidence of medullary carcinoma in various  study was 5% (Mc Divitt RW, et al., 
1968), 2.7% (Ellis IO, et al., 1992. loc.cit.), 1% (Sloane, et al., 1999). In our study 
the tumor fulfilled all the criteria for designation of typical medullary carcinoma 
laid down by Ridolfi, et al., (1977. loc.cit.).
Mucinous carcinoma constituted 1.3% of the total breast carcinoma studied. 
Sloane JP, et al., (1999. loc.cit.) found an incidence less than 5%, Dixon JM, et al., 
(1985. loc.cit.) observed an incidence of 2%. Ellis IO, et al., (1992. loc.cit.) found 
that the mucionus carcinoma has a better prognosis than infiltrating ductal and 
lobular carcinoma. He found an over all 10 year survival of 80%, a similar 
observations was made by Toikanen S and Kujari H (1989).
           Invasive papillary carcinoma constituted (1.3%) of the cases under our 
study. Most of the studies on the tumor have found an incidence of less than 1% 
(Sloane JP, et al., 1999 loc.cit).
We had one case of neuroendocrine carcinoma in a patient of 65 years. The 
mass was subareolar in location and presented with bloody nipple discharge. The 
tumor was composed of sheets of uniform small cells arranged in nests and cords 
with palisading.
Immunohistochemistry revealed positivity for synaptophysin. Papotti M, et 
al., (1989) concluded that most neuroendocrine carcinoma of breast exhibit 
positivity for synaptophysin. It is considered to be a more reliable histochemical 
marker. Scopsi L, et al., (1992) found positivity with chromogranin A or B in 86% 
of the cases and neuron specific enolase in 100% of cases, Andreola S, et al., 
(1988) have observed variable positivity for gastrin, insulin and bombesin.
Malignant lymphoma of the breast may be primary or more usually 
secondary. We had a single case of primary malignant lymphoma involving the 
breast. Mambo NC, et al., (1977) found 0.12% of cases and Bobrow LG, et al., 
(1993) 0.3% of cases. Even among the extra-nodal lymphomas, breast is an 
uncommon site. It mostly occurs in older women with a variable clinical course. 
(Hugh JC, et al., (1990)). Immunohistochemical markers done on this case showed 
positivity for T cell marker.
Carbone  A, et al., (1982) found a predominance of B cell pheno type in 
most cases. Cohen P and Brooks JJ (1991), Mattia AR, et al., (1993), had a similar 
observation.
The prognosis of primary lymphoma of breast has varied in different studies, 
but actuarial survival appears to be about 50% over 5 years. [De Cosse JJ, et al., 
(1962) ; mambo NC, et al., (1977) loc.cit]. Tumor size and axillary node 
involvement do not have the prognostic significance as in invasive ductal 
carcinoma (NST) tumors.
Histological type and AgNOR : 
The correlation between histological  type and AgNOR was done and we 
found that  the mean AgNOR value in  invasive ductal  carcinoma with comedo 
pattern was highest  (3.47),  followed by Invasive ductal  carcinoma (No special 
type)  with a mean AgNOR of 3.07. Lobular carcinoma has the least mean AgNOR 
of 2.7. Carcinoma of other special types including medullary, mucinous, papillary 
and neuroendocrine carcinoma and lymphoma together had a mean AgNOR of 
2.78 which is less than that of Invasive ductal carcinoma. This correlation has a 
significant p value of 0.0023 (Table : 18).
Our study is in concordance with the study by Aaltomaa S, et al., (1993), 
who correlated AgNOR with histological type and found it to be significant with a 
p value of 0.003.
Browser ST, et al., (1995) loc.cit suggested that in invasive tumors, comedo 
carcinoma are associated with poor prognostic factors. This correlates well with 
our  observation.  All  the  3 cases of  invasive  ductal  carcinoma (comedo) had a 
higher AgNOR value and higher mean NPI score.
Studies by Perez–Mesa CM, (1979), Ermilova VD, et al., (1990) loc.cit, Ellis 
IO, et al., (1992) loc.cit also confirm that histological typing of breast carcinoma 
can provide useful prognostic information.
Clinical stage and Histological grade:
Cases of invasive ductal carcinoma were alone included in this correlative 
exercise and the tumors were graded according to Nottingham modification of 
Bloom and Richardson system. We had 69 cases in this category (Table 9). Three 
cases of IDC presented as stage I lesion. The histological grade of these tumors 
revealed that all the 3 cases (100%) were of grade I malignancy.
There  was  an  excellent  correlation  between  the  clinical  staging  and 
histological grading. All the 21 cases presenting as stage II disease, fell into the 
grade II category.
We had 42 cases presenting as stage III disease. Histological grading done 
on  these  cases  reveal  that  majority  of  the  cases  (57.1%)  were  of  grade  III 
malignancy followed by 40.5% of cases of grade II malignancy and there was a 
single case present as grade I lesion.
All the 3 cases presenting as stage IV disease were found to be of higher 
histological grade of malignancy. This observation is similar to that of Rosen PP, 
et  al.,  (1989)  who  observed  significant  increase  in  the  histological  grade  of 
malignancy with advancing clinical stage. The other unfavourable factors could be 
increase in tumor size, perimenopausal status, number of involved axillary nodes, 
and presence of lymphatic or vascular emboli. So an analysis of the clinical stage 
and histological grade were complementary in assessing the prognosis of the case 
of carcinoma breast.
Size and grade:
In analysing the cases of breast carcinoma, we attempted a correlation 
between the histological grade of malignancy and the mean tumor diameter.
We found in grade I lesion the mean tumor size was 3.08 cm, for grade II 
lesions it was 5.55 cm and grade III lesions had a mean tumor size of 8.2 cm. 
These results were statistically significant with a p value of 0.0001 (Table : 10).
This correlates well with the observation of Sundquist M, et al., (1999) who 
found an accurate estimation of the tumor size together with the grade and lymph 
nodal  status  constituted  statistically  significant  predictors  of  survival.  So  the 
parameter  have  been  rightly  incorporated  in  the  calculation  of  Nottingham 
prognostic Index (Galea MH, et al., 1992.  loc.cit).
Size and nodal status:
Axillary nodal involvement remain an essential prognostic factor for breast 
cancer patients, as it implies the necessity of systemic adjuvant treatment and loco 
regional radiation.
As tumor size and the lymphnodal status are independent prognostic variable 
in carcinoma breast we made an attempt to correlate the mean tumor size with that 
of the lymph node status.
The mean tumor  size  was 5.65 cm in patients  with no detectable  lymph 
nodes (stage I),  the size was 5.5 cm in stage II cases and 8.13 cm in stage III 
group. The results were statistically significant with a p value of 0.0018 (Table : 
11). This is in coherence with the observation made by Rudan I, et al., (1994), who 
analysed  the  various  prognostic  factors  in  patients  with  node  negative  breast 
cancer. They concluded that the tumor size and histological grade were significant 
prognostic parameter.
Cutuli. B, et al., (2001) found that the tumor size, and histological type were 
significant  predictors  of  prognosis,  which  correlate  well  with  our  observation. 
Siddiqui T, et al., (2002) evaluated a series of helpful predictors of axillary node 
involvement.  They  found  that  the  tumor  size  was  one  of  the  very  significant 
predictor. The other predictors include age of menarche, duration of symptoms, 
and  skin  and  nipple  involvement.  This  is  in  support  of  our  observation  of  a 
proportional increase in the tumor size with increase in the number of axillary 
nodes involved. Shen ZZ, (1991) studied a series of 2189 cases of radical surgery 
and showed a  linear  relation  between tumor  size  and percentage  of  case  with 
positive lymph node involvement. Similar results were observed by Barranger E, 
et al., (2005).
Rack B, et al., (2003) had a similar observation in case of recurrent breast 
cancer and he found a significant correlation between the tumor size and nodal 
status. 
Vascular invasion with Grade and Lymph Node Stage:
High grade malignant tumors have a shorter tumor doubling time, are less 
cohesive and often with irregular borders and tend to invade by small aggregates 
of  tumor  cells.  The  presence  of  vascular  invasion  provides  considerable 
information on the aggressiveness of the neoplasm. We tried to incorporate this 
hypothesis in our study and we correlated the incidence of vascular invasion with 
that of the histological grade and lymph node stage of tumors. Vascular invasion 
was observed in 47 case (58.8%) and was absent in 33 cases (41.2%). 69 cases of 
IDC were included in this study of incidence of vascular invasion in each grade of 
breast  carcinoma. The percentage of vascular  invasion was higher  in grade III 
malignancy (Table: 13). Vascular invasion was seen in 21.4% of stage I lymph 
node status and increased with the increase in number of nodes involved (Table: 
14).
This observation correlates well with that of Pinder SE, et al., (1994) loc.cit 
who found that the vascular invasion was strongly associated with lymph node 
stage, tumor size, histological grade and histological type of the tumor. 
Hartveit F, et al., (1984), demonstrated that the presence or absence of tumor 
cells in the efferent nodal vessels can be used as a measure of nodal stage.
In the analysis done by Pinder SE, et al., (1994) loc.cit in a series of 1704 
invasive breast carcinoma cases, vascular invasion was strongly associated with 
lymph node stage which was statistically significant with a p value of < 0.001. 
Blood vessel invasion and axillary lymph node involvement were examined by 
Weigand RA, et al., (1982. loc.cit.). They suggested that blood vessel invasion in 
combination with node status, is a prognostic indicator with high discriminatory 
power.
The study by Centintas SK, et al., (2006) shows that the presence of 
lymphatic vessel invasion increased the risk of axillary node involvement with a p 
value of 0.0003.
Resection Margin with clinical stage and Histological grade :
Assessment of surgical resected margin is commonly used as a guide to the 
relative aggressiveness of therapy and to predict the rate of relapse.
In our study, resected margin was free in all the case of stage I breast cancer 
and majority of 24 cases (88.9%) had free margins in stage II. This was reduced to 
30 cases  (68.2%) in case  of  stage  III  disease  and 75% of  stage IV cases  had 
involvement of the resection margin (Table 12).
Wager DE, et al., (1997. loc.cit.) had a similar observation while evaluating 
the status of the resection margins as a predictor of residual tumor burden.
A similar correlation was done between the histological grade of the tumor 
and the status of the resection margin. The invasive ductal carcinoma were only 
included in this correlative exercise and we found resected margin was free in all 
the 4 case of grade I malignancy. 33 cases (64.7%) of grade II malignancy had free 
margin and only 14 cases (27.5%) of grade III malignancy had free margin.
This clearly indicates that, as the histological grade of malignancy increases, 
the involvement of the resection margin also increases and contribute to one of the 
prognostic predictors in cases of carcinoma breast.
Lymph Node Status and Grade:
Axillary node involvement is an important prognostic variable in the 
management of patients with primary breast cancer. It is a time - dependent 
variable but the studies by Jatoi I, et al., (1999. loc.cit.) and Rack B, et al., (2003. 
loc.cit.) showed that it is also a marker of an aggressive phenotype.
We correlated lymph node stage with the histological grade of the tumor. 
Among grade I cases 50% were of lymph node stage I and 50% were of stage II.  
Among grade II cases, maximum number of cases (50%)  were of stage II nodal 
status and 5.3% of cases were of stage III nodal status.  Most of grade III cases 
(59.3%) fell into stage III lymph node status (Table 15).
Rudan I, et al., (1994. loc.cit.) concluded that among stage I patients, grade 
and tumor size can serve as helpful predictors of 5-year overall survival. Similar 
observations were made by Nottage MK, et al., (2006).
Nottingham Prognostic Index (NPI) :
The NPI is an integrated prognostic index used to predict patient survival for 
women with invasive breast cancer. We have calculated the NPI in all our cases 
(Table: 7).
In our study, 20 cases (29%) had a good NPI score, 24 cases (34.8%) had an 
average score and 25 cases (36.2%) had poor NPI scores.
These scores were then correlated with the clinical stage of the disease. We 
have found a NPI score of 1.97 in stage I, 3.57 in stage II, 5.62 in stage III and 
7.85 in stage IV (Table :16). This very well correlates with the studies of Kollias J,  
et al., (1999), Haybittle JL, et al., (1982), Galea MH, et al., (1992), and Okugawa 
H, et al., (2005) who suggested an observation of higher the score worser is the 
prognosis.
We also correlated the NPI with the AgNOR values. All the cases with a 
good NPI had a low AgNOR score and patients with poor NPI had a higher 
AgNOR score (Table: 20).
This correlates well with the observation of Subramanian S, et al., (1996), 
who  found  that  the  AgNOR  count  was  significantly  related  to  the  cell  size, 
histological grade and the presence of nodal metastasis. Calculation of the NPI and 
AgNOR is of immense value in predicting the prognosis  and disease free survival 
status.
The  correlation  between  vascular  invasion  and  NPI  score  was  also 
significant with a p value of 0.0001. The mean NPI score in tumors with vascular 
invasion was 5.85 and in tumors without vascular invasion was 3.74.
Stage and AgNOR :
The  relation  between  TNM staging  and  argyrophilic  nucleolar  organizer 
regions  (AgNOR)  within  human  breast  cancer  cells  was  analyzed.  The  mean 
AgNOR count for stage IV was highest (3.28) and that for stage I was low (2.52). 
Stage II and stage III tumor had intermediate value of 2.84 and 3.2 respectively. 
This correlation was significant with a p value of 0.0001(Table 17).
Aubele M, et al., (1994) investigated the correlation of AgNOR features with 
other  prognostic  variable  and  found  that  TNM  staging  showed  significant 
correlation with AgNOR count.
Kumar  A,  et  al.,  (1997)  evaluated  AgNORs  in  46  patients  with  primary 
breast carcinoma and correlated these with clinical prognostic parameters. Their 
results shows a statistically significant increase in correlation with increase in the 
size of the tumor, stage of the cancer and number of metastatic lymph nodes.
These results indicate that breast tumors with a higher AgNOR count, even 
at  the initial  stage,  have a poor prognosis and require aggressive treatment for 
better control of the disease.
Grade and AgNOR:
The relevance of silver stained NORs for prognosis in breast  cancer was 
investigated  by  correlating  it  with  modified  Bloom– Richardson  (Nottingham) 
grading. The mean AgNOR count in grade III tumors was 3.4 which fell to 2.93 in 
grade II and 2.53 in grade I tumors with a significant p value of 0.0001 (Table 19).
Aubele  M,  et  al.,  (1994.loc.cit.)  found significant  differences  in  AgNOR 
score  with  Bloom–Richardson  gradings  I,  II  and  III.  Ofner  D,  et  al.,  (1996) 
suggested  that  AgNOR  count  was  statistically  significantly  correlated  with 
histological grade and hormone receptor status of tumors. Increase AgNOR count 
was  statistically  significantly  associated  with  early  tumor  relapse  and  cancer 
related death.
Aaltomaa S,  et  al.,  (1993.  loc.cit.)  suggested that  the AgNOR count  was 
related  significantly  to  histological  grade  [p  <  0.001)  histological  type,  and 
hormone  receptor  content.  But  Gupta  GR,  et  al.,  (1997)  found  no  correlation 
between AgNOR and histological grade while it correlated with tumor size and 
axillary lymph node metastasis.
In our study AgNOR count correlated well with pattern of vascular invasion. 
The mean AgNOR count in tumors with vascular invasion was 3.11 where as the 
same  in  tumors  without  vascular  invasion  was  2.95.  This  was  found  to  be 
statistically significant with a p value of  0.244.
Estrogen Receptor and Progesterone Receptor Status (ER/PR):
The hormone receptor status had no statistically significant correlation with 
the  other  prognostic  parameters  like  grade,  lymph  nodal  status  and  vascular 
invasion. Roberts AN, et al., (1981) had a similar observation.
Collett K, et al., (1998), Aamdal S, et al., (1984) loc.cit have suggested that 
the ER/PR status can be considered as an independent factor, more of therapeutic 
importance rather than predicting the prognosis.
However  inclusion  of  the  evaluation  of  ER/PR  status  along  with  other 
proliferative parameters is more beneficial to the patients to assess the nature of 
adjuvant chemotherapy.
CONCLUSION
The role of histopathology in the provision of prognostic information has 
been well established in a number of malignant tumors.
Mammographic screening detects breast cancers which are different in 
biological behaviour from those which present symptomatically. Further, there has 
been an increase in the number of treatment options, both surgical and medical. 
The attitude of patients is changing and more women are exercising their right to 
participate in the management and therapeutic decisions.
These developments highlight the importance of evaluation of prognostic 
factors in the management of patients with breast cancer. The most important 
reason for the use of prognostic factors are to identify patients.
- Whose prognosis is so good that adjuvant therapy after local  
surgery would not be cost-beneficial.
- Whose prognosis is so poor that a more aggressive adjuvant therapy 
would be warranted.
- Who are likely to respond to particular types of therapy.
 In our study we evaluated the prognostic significance of histological typing, 
staging, grading, tumor size, vascular invasion, resection margin involvement, 
AgNOR and NPI.
There was statistically significant association between these individual 
prognostic parameters.
So we conclude that a proper evaluation  of the morbid anatomy, exact tumor 
size, clinical stage, histological grade, histological subtype lymph node status and 
margins are mandatory for prognostication. 
Additional parameters like the NPI and AgNOR can be done along with the 
above parameters to give a comprehensive  report regarding the patients prognosis.
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PROFORMA – A
MACROSCOPIC STUDY
Name & Age of the Patient :
I.P. No. :
Path Ref. No :
Type of specimen :
Whole size of the specimen : cm
Maximum diameter of tumour : cm
Disease Extent :
Excision Margin :
Overlying skin :
Nipple & Areola :
Number of lymph nodes :
Size – Largest :
Smallest :
Stage of the tumour :
PROFORMA - B
MICROSCOPIC FEATURES
1. Histological subtype :
2. Histological grade :
3. Tumour size :
4. Resection Margin Involvement :
5. Vascular Invasion :
6. Lymph node status
Total No. of nodes :
Positive :
Negative :
7. Quantification of AgNORs :
8. Calculation of Nottingham
      Prognostic Index :
9. ER/PR status :
